Clinical and laboratory data of study participants
| SLE (n=7) | Rhupus (n=7) | RA (n=10) | |
| Age, years | 33 (27–40) | 48 (43–50) | 47 (42–60) |
| Female, n (%) | 7 (100) | 7 (100) | 7 (70) |
| Disease duration, years | 6 (3–15) | 2 (1–8) | 3 (1–13) |
| Comorbidities | |||
| Antiphospholipid syndrome, n (%) | 2 (28) | 1 (14) | 0 |
| Diabetes, n (%) | 0 | 1 (14) | 5 (50) |
| Systemic hypertension, n (%) | 0 | 0 | 2 (20) |
| Main clinical features | |||
| Mucocutaneous involvement, n (%) | 7 (100) | 7 (100) | 0 |
| Arthritis, n (%) | 7 (100) | 7 (100) | 10 (100) |
| Renal involvement, n (%) | 4 (57) | 1 (14) | 0 |
| Neurological involvement, n (%) | 0 | 0 | 0 |
| Haematological, n (%) | 4 (57) | 5 (71) | 0 |
| Antirheumatic therapy | |||
| Glucocorticoids, n (%) | 5 (71) | 3 (43) | 4 (40) |
| Azathioprine, n (%) | 3 (43) | 1 (14) | 0 |
| Mofetil mycophenolate, n (%) | 2 (28) | 1 (14) | 0 |
| Methotrexate, n (%) | 3 (43) | 5 (71) | 10 (100) |
| Leflunomide, n (%) | 0 | 0 | 3 (30) |
| Antimalarials, n (%) | 5 (71) | 6 (85) | 6 (60) |
| Laboratory values | |||
| Leucocytes, 109/L | 5.3 (3.9–5.7) | 5.0 (4.1–5.7) | 7.9 (7.0–10.4) |
| Haemoglobin, g/L | 138 (111–141) | 129 (119–143) | 137 (130–151) |
| Platelets, 109/L | 255 (235–269) | 271 (143–352) | 282 (233–365) |
| Serum creatinine, mg/dL | 0.6 (0.5–0.7) | 0.6 (0.5–0.8) | 0.7 (0.6–0.9) |
| C-reactive protein, mg/L | 5.1 (0.5–7.7) | 8.9 (6.2–29.5) | 5.9 (1.4–11.2) |
| C3, mg/L | 80.3 (75.4–120.9) | 121.8 (103.6–147.9) | – |
| C4, mg/L | 15.3 (12.0–39.2) | 22.0 (15.9–28.3) | – |
| ESR (mm/hour) | 19.0 (5.0–23.0) | 23.0 (13.0–32.0) | 13.5 (11.2–25.7) |
| Rheumatoid factor ≥20 IU/mL, + (%) | 1 (14) | 7 (100) | 10 (100) |
| Antinuclear antibodies ≥1:160, + (%) | 7 (100) | 7 (100) | – |
| Anti-Ro/SSA antibodies, + (%) | 1 (14) | 4 (57) | – |
| Anti-La/SSB antibodies, + (%) | 0 | 4 (57) | – |
| SLEDAI-2K | 4 (2–8) | 4 (0–4) | – |
| DAS28-CRP | – | 2.8 (1.5–3.0) | 2.3 (1.5–3.1) |
Data are expressed as median (IQR) unless otherwise specified.
DAS28-CRP, Disease Activity Score 28-joint count C-reactive protein; ESR, erythrocyte sedimentation rate; RA, rheumatoid arthritis; SLEDAI-2K, SLE Disease Activity Index 2000.